MedTrace Logo

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

NCT03065192 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-03-21

No results posted yet for this study

Summary

Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

Conditions

Interventions

DRUG

VY-AADC01

Single dose, neurosurgically infused, bilaterally into the striatum.

Sponsors & Collaborators

  • Voyager Therapeutics

    collaborator INDUSTRY

  • Neurocrine Biosciences

    lead INDUSTRY

Principal Investigators

  • Steve Hersch, MD · Voyager Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-11
Primary Completion
2021-08-10
Completion
2021-08-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065192 on ClinicalTrials.gov